title: Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women.
abstract: A consensus view of soyabean phyto-oestrogens in clinical interventions in post-menopausal women is presented that is based on data from the EU-funded project Phytohealth. The phyto-oestrogens, primarily genistein and daidzein, were given as soyabean-protein isolates, whole-soyabean foods or extracts, supplements or pure compounds. A comprehensive literature search was conducted with well-defined inclusion or exclusion criteria. For areas for which substantial research exists only placebo-controlled double-blind randomised controlled trials (RCT) conducted on healthy post-menopausal women were included. For emerging areas all available human studies in post-menopausal women were reviewed. In order to make cross comparisons between studies the doses of isoflavones were calculated as aglycone equivalents. There is a suggestion, but no conclusive evidence, that isoflavones from the sources studied so far have a beneficial effect on bone health. The consumption of whole-soyabean foods and soyabean-protein isolates has some beneficial effects on lipid markers of cardiovascular risk. The consumption of isolated isoflavones does not affect blood lipid levels or blood pressure, although it may improve endothelial function. For menopausal symptoms there is currently limited evidence that soyabean-protein isolates, soyabean foods or red-clover (Trifolium pratense L.) extract are effective but soyabean isoflavone extracts may be effective in reducing hot flushes. There are too few RCT studies to reach conclusions on the effects of isoflavones on breast cancer, colon cancer, diabetes or cognitive function. The health benefits of soyabean phyto-oestrogens in healthy post-menopausal women are subtle and even some well-designed studies do not show protective effects. Future studies should focus on high-risk post-menopausal women, especially in the areas of diabetes, CVD, breast cancer and bone health.
authors.affiliation: Centre for Metabolic Bone Disease, Hull Royal Infirmary, UK. a.cassidy@uea.ac.uk
authors.forename: Aedin
authors.initials: A
authors.lastname: Cassidy
authors.forename: Paola
authors.initials: P
authors.lastname: Albertazzi
authors.forename: Inge
authors.initials: I
authors.lastname: Lise Nielsen
authors.forename: Wendy
authors.initials: W
authors.lastname: Hall
authors.forename: Gary
authors.initials: G
authors.lastname: Williamson
authors.forename: Inge
authors.initials: I
authors.lastname: Tetens
authors.forename: Steve
authors.initials: S
authors.lastname: Atkins
authors.forename: Heide
authors.initials: H
authors.lastname: Cross
authors.forename: Yannis
authors.initials: Y
authors.lastname: Manios
authors.forename: Alicja
authors.initials: A
authors.lastname: Wolk
authors.forename: Claudia
authors.initials: C
authors.lastname: Steiner
authors.forename: Francesco
authors.initials: F
authors.lastname: Branca
mesh_terms: D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000494:pharmacology; D001943:Breast Neoplasms / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D005260:Female; D019833:Genistein / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007529:Isoflavones / Q000008:administration & dosage / Q000494:pharmacology; D009369:Neoplasms / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D048789:Phytoestrogens / Q000008:administration & dosage / Q000494:pharmacology*; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D013025:Glycine max / Q000737:chemistry
chemical_list: D016588:Anticarcinogenic Agents; D007529:Isoflavones; D048789:Phytoestrogens; C004742:daidzein; D019833:Genistein